Potent P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial.
BACKGROUND Dual antiplatelet therapy (DAPT) for 12 months is the current standard of care for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Recent evidence indicates that potent oral P2Y12 inhibitor-based single antiplatelet therapy (SAPT)...